E-resources
-
AYAS, Mouhab; SABER, Wael; AL-SERAIHY, Amal; BATTIWALLA, Minoo; CAMITTA, Bruce M; OLSSON, Richard; BAJWA, Rajinder S; BONFIM, Carmem M; PASQUINI, Ricardo; MACMILLAN, Margaret L; GEORGE, Biju; COPELAN, Edward A; DAVIES, Stella M; WIRK, Baldeep; AL JEFRI, Abdullah; FASTH, Anders L; GUINAN, Eva C; HORN, Biljana N; LEWIS, Victor A; SLAVIN, Shimon; STEPENSKY, Polina; BIERINGS, Marc; GALE, Robert Peter; HARRIS, Richard E; HALE, Gregory A; SOCIE, Gerard; LERADEMACHER, Jennifer; THAKAR, Monica; JOACHIM, H; DEEG, J
Journal of clinical oncology, 05/2013, Volume: 31, Issue: 13Journal Article
Allogeneic hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi anemia (FA). Data on outcomes in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome (MDS), or acute leukemia have not been separately analyzed. We analyzed data on 113 patients with FA with cytogenetic abnormalities (n = 54), MDS (n = 45), or acute leukemia (n = 14) who were reported to the Center for International Blood and Marrow Transplant Research from 1985 to 2007. Neutrophil recovery occurred in 78% and 85% of patients at days 28 and 100, respectively. Day 100 cumulative incidences of acute graft-versus-host disease grades B to D and C to D were 26% (95% CI, 19% to 35%) and 12% (95% CI, 7% to 19%), respectively. Survival probabilities at 1, 3, and 5 years were 64% (95% CI, 55% to 73%), 58% (95% CI, 48% to 67%), and 55% (95% CI, 45% to 64%), respectively. In univariate analysis, younger age was associated with superior 5-year survival (≤ v > 14 years: 69% 95% CI, 57% to 80% v 39% 95% CI, 26% to 53%, respectively; P = .001). In transplantations from HLA-matched related donors (n = 82), younger patients (≤ v > 14 years: 78% 95% CI, 64% to 90% v 34% 95% CI, 20% to 50%, respectively; P < .001) and patients with cytogenetic abnormalities only versus MDS/acute leukemia (67% 95% CI, 52% to 81% v 43% 95% CI, 27% to 59%, respectively; P = .03) had superior 5-year survival. Our analysis indicates that long-term survival for patients with FA with cytogenetic abnormalities, MDS, or acute leukemia is achievable. Younger patients and recipients of HLA-matched related donor transplantations who have cytogenetic abnormalities only have the best survival.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.